Literature DB >> 7660203

Severe obesity: expensive to society, frustrating to treat, but important to confront.

L F Martin1, S M Hunter, R M Lauve, J P O'Leary.   

Abstract

Obesity is a major contributor to chronic and costly diseases and disabilities. More than 30% of American adults are obese, and the percentage has been rising for 20 years. A recent estimate placed the direct economic costs of obesity at more than $39.3 billion, or 5.5% of all medical expenditures in the mid-1980s. These numbers underestimate prevalence and cost because the studies designed to monitor our nation's health problems have ignored the most obese segment of the population-individuals weighing more than 350 pounds. The methods used to treat obesity are controversial, some of them lacking appropriate evaluation. Physicians have been reluctant to treat obese people because of the intensity and duration of an effective treatment program. Finally, many treatments fail in the long term and therefore are not considered cost effective. Multiple treatment options are currently available, and this review presents data to aid physicians in selection of the best therapy to help their patients. As cost advantages of comprehensive care of obese patients become more obvious under capitated financing systems, further investigation should focus on mechanisms of choosing more individualized care plans to defined subsegments of the obese population to make care more cost effective.

Entities:  

Mesh:

Year:  1995        PMID: 7660203     DOI: 10.1097/00007611-199509000-00001

Source DB:  PubMed          Journal:  South Med J        ISSN: 0038-4348            Impact factor:   0.954


  12 in total

1.  A potential and novel therapy for obesity: "appendix" electrical stimulation in dogs.

Authors:  Yong Lei; Jiande D Z Chen
Journal:  Obes Surg       Date:  2011-03       Impact factor: 4.129

2.  Gastroesophageal reflux disease and esophageal motility in morbidly obese patients submitted to laparoscopic adjustable silicone gastric banding or laparoscopic vertical banded gastroplasty.

Authors:  Fabrizio Rebecchi; Stefano Rocchietto; Claudio Giaccone; Ahmed Talha; Mario Morino
Journal:  Surg Endosc       Date:  2010-07-30       Impact factor: 4.584

3.  Parameters of obesity in African-American women.

Authors:  M T Railey
Journal:  J Natl Med Assoc       Date:  2000-10       Impact factor: 1.798

4.  Effect of acute gastric electrical stimulation on the systemic release of hormones and plasma glucose in dogs.

Authors:  J H Xing; Y Lei; H R Ancha; R F Harty; J D Chen
Journal:  Dig Dis Sci       Date:  2007-01-09       Impact factor: 3.199

5.  Revisional surgery for failed vertical-banded gastroplasty.

Authors:  Sarah Tevis; Michael J Garren; Jon C Gould
Journal:  Obes Surg       Date:  2011-08       Impact factor: 4.129

6.  PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene.

Authors:  K Schoonjans; J Peinado-Onsurbe; A M Lefebvre; R A Heyman; M Briggs; S Deeb; B Staels; J Auwerx
Journal:  EMBO J       Date:  1996-10-01       Impact factor: 11.598

7.  Laparoscopic gastric bypass as a reoperative bariatric surgery for failed open restrictive procedures.

Authors:  J de Csepel; R Nahouraii; M Gagner
Journal:  Surg Endosc       Date:  2001-02-06       Impact factor: 4.584

8.  Therapeutic potential of gastric electrical stimulation for obesity and its possible mechanisms: a preliminary canine study.

Authors:  Hui Ouyang; Jieyun Yin; J D Z Chen
Journal:  Dig Dis Sci       Date:  2003-04       Impact factor: 3.199

Review 9.  Laparoscopic surgical concepts of morbid obesity.

Authors:  K Miller; E Hell
Journal:  Langenbecks Arch Surg       Date:  2003-10-30       Impact factor: 3.445

10.  Conversion of vertical banded gastroplasty to Roux-en-Y gastric bypass results in restoration of the positive effect on weight loss and co-morbidities: evaluation of 101 patients.

Authors:  Ruben Schouten; Francois M H van Dielen; Wim G van Gemert; Jan Willem M Greve
Journal:  Obes Surg       Date:  2007-05       Impact factor: 4.129

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.